Description of Invention: The present invention discloses the use of IL-21 for cancer therapy and/or cancer prevention. When compared to similar cytokines, IL-21 has shown substantial anticancer activity and reduced toxicity in murine models.
IL-21 belongs to the class I family of cytokines and is closely related to IL-2 and IL-15. Some cancer patients have shown significant response to administration of IL-2. However, IL-2 has also been associated with severe toxicity leading to a variety of undesirable side effects. This invention attempts to resolve the toxicity concerns and presents a new therapy for cancer prevention and treatment.
Applications: Method to treat and prevent cancer
Advantages: Targeted therapy to minimize negative side effects of IL-2 cancer therapeutics
Development Status: Pre-clinical
Inventors: Patrick Hwu (NCI) Gang Wang (NCI) Warren J Leonard (NHLBI) Rosanne Spolski (NHLBI)
Spolsi R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57-79. [ PMID: 17953510 ]
Leonard WJ, Spolski R. Interleulin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol. 2005 Sep;5(9):688-698. [ PMID: 16138102 ]
Wang G, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003 Dec15;63(24):9016-9022. [ PMID: 14695220 ]
Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol. 2008 Jun;20(3):295-301. [ PMID: 18554883 ]
Licensing Status: Available for licensing
Portfolios: Cancer Cancer - Therapeutics
For Licensing Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4633 Fax: 301-402-0220